Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene.

Hatch E, Sconce EA, Daly AK, Kamali F.

J Thromb Haemost. 2006 May;4(5):1158-9. No abstract available.

2.

Predictive value of the vitamin K epoxide reductase complex subunit 1 G-1639A and C1173T single nucleotide polymorphisms in retinal vein occlusion.

Ortak H, Söğüt E, Demir H, Ardagil A, Benli I, Sahin S.

Clin Exp Ophthalmol. 2012 Sep-Oct;40(7):743-8. doi: 10.1111/j.1442-9071.2012.02780.x. Epub 2012 May 17.

PMID:
22394334
3.

A genotyping method for VKORC1 1173C > T by Pyrosequencing technology.

Enström C, Osman A, Lindahl TL.

Scand J Clin Lab Invest. 2008;68(5):427-30.

PMID:
19172700
4.

Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics.

Spohn G, Geisen C, Luxembourg B, Sittinger K, Seifried E, Bönig H.

Mol Diagn Ther. 2011 Feb 1;15(1):13-9. doi: 10.2165/11588300-000000000-00000. Erratum in: Mol Diagn Ther. 2011 Jun 1;15(3):142-4.

PMID:
21469766
5.

Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.

Aomori T, Yamamoto K, Oguchi-Katayama A, Kawai Y, Ishidao T, Mitani Y, Kogo Y, Lezhava A, Fujita Y, Obayashi K, Nakamura K, Kohnke H, Wadelius M, Ekström L, Skogastierna C, Rane A, Kurabayashi M, Murakami M, Cizdziel PE, Hayashizaki Y, Horiuchi R.

Clin Chem. 2009 Apr;55(4):804-12. doi: 10.1373/clinchem.2008.115295. Epub 2009 Jan 30.

6.

A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.

Stepien E, Branicka A, Ciesla-Dul M, Undas A.

J Appl Genet. 2009;50(4):399-403. doi: 10.1007/BF03195700.

PMID:
19875892
7.

[Vitamin K epoxide reductase complex 1 gene polymorphism and warfarin dose requirement in Chinese patients].

Jiang NX, Song J, Xu B.

Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Jul;35(7):652-4. Chinese.

PMID:
17961434
8.

SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.

Huang SW, Li Q, Zhu SY, Li L, Xiong F, Jia YK, Xu XM.

Clin Chem Lab Med. 2009;47(1):26-31. doi: 10.1515/CCLM.2009.008.

PMID:
19117406
9.

Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study.

Suh JW, Baek SH, Park JS, Kang HJ, Chae IH, Choi DJ, Park HJ, Kim PJ, Seung KB, Kim HS.

Am Heart J. 2009 May;157(5):908-12. doi: 10.1016/j.ahj.2009.02.001. Epub 2009 Mar 21.

PMID:
19376320
10.

Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: A pilot study.

Holzer G, Grasse AV, Zehetmayer S, Bencur P, Bieglmayer C, Mannhalter C.

Transl Res. 2010 Jul;156(1):37-44. doi: 10.1016/j.trsl.2010.05.005. Epub 2010 May 27.

PMID:
20621035
11.

Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study.

Lacut K, Larramendy-Gozalo C, Le Gal G, Duchemin J, Mercier B, Gourhant L, Mottier D, Becquemont L, Oger E, Verstuyft C.

J Thromb Haemost. 2007 Oct;5(10):2020-4.

12.

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA.

Clin Pharmacol Ther. 2006 Apr;79(4):291-302. Epub 2006 Feb 28.

PMID:
16580898
13.

Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population.

Larramendy-Gozalo C, Yang JQ, Verstuyft C, Bodin L, Dubert L, Zhang Y, Xu C, Fan L, Jaillon P, Becquemont L.

Basic Clin Pharmacol Toxicol. 2006 Jun;98(6):611-3. No abstract available.

14.

Exciton Primer-mediated SNP detection in SmartAmp2 reactions.

Lezhava A, Ishidao T, Ishizu Y, Naito K, Hanami T, Katayama A, Kogo Y, Soma T, Ikeda S, Murakami K, Nogawa C, Itoh M, Mitani Y, Harbers M, Okamoto A, Hayashizaki Y.

Hum Mutat. 2010 Feb;31(2):208-17. doi: 10.1002/humu.21177.

PMID:
20052755
15.

Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose.

Quteineh L, Verstuyft C, Descot C, Dubert L, Robert A, Jaillon P, Becquemont L.

Thromb Haemost. 2005 Sep;94(3):690-1. No abstract available.

PMID:
16268497
16.

[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].

Loriot MA, Beaune P.

Rev Med Interne. 2006 Dec;27(12):979-82. Epub 2006 Oct 11. Review. French.

PMID:
17070618
17.

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.

Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE.

Pharmacogenet Genomics. 2005 Oct;15(10):687-91.

PMID:
16141794
18.

VKORC1 and the vitamin K cycle.

Garcia AA, Reitsma PH.

Vitam Horm. 2008;78:23-33. doi: 10.1016/S0083-6729(07)00002-7. Review.

PMID:
18374188
19.

miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle.

Pérez-Andreu V, Teruel R, Corral J, Roldán V, García-Barberá N, Salloum-Asfar S, Gómez-Lechón MJ, Bourgeois S, Deloukas P, Wadelius M, Vicente V, González-Conejero R, Martínez C.

Mol Med. 2013 Jan 22;18:1466-72. doi: 10.2119/molmed.2012.00062.

20.

Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.

Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD.

Thromb Haemost. 2005 Jan;93(1):23-6.

PMID:
15630486

Supplemental Content

Support Center